Chapter 94: Drugs for Acute Care

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we think about giving a patient a medication in primary care,

it's

a slow burn.

Definitely.

Like you write a prescription, they take a pill every morning, and maybe in like three months you check their labs or their blood pressure to see if their body adapted.

It's a marathon.

It really is.

It's a marathon where the physiology has plenty of time to, you know, adjust, compensate and react to whatever pharmacological intervention you're introducing.

Right.

You are gently nudging the system.

Exactly.

You're nudging it.

But then you walk into an emergency department or an ICU or an operating room.

Oh, man.

And suddenly that marathon turns into a high speed car chase.

That's the perfect way to put it.

We are pushing intravenous drugs that alter the fundamental pathophysiology of a human being in literally a matter of seconds.

Yeah.

We aren't just nudging the body anymore.

We are completely overriding it.

Which means the margin for error essentially vanishes.

Right.

It's gone.

You have to understand exactly what you are doing at the receptor level because those compensatory mechanisms you usually rely on, they're either failing or being intentionally bypassed by us.

And that's exactly why we're here today.

We are pulling out some critical guidelines from Chapter 94 of Lane's Pharmacotherapeutics.

Such a crucial chapter.

It really is.

We're going to look at the drugs used when a patient is actively crashing or heading into surgery.

And we're speaking directly to you, the advanced practice nursing and physician assistant students out there.

Because you'll be the ones pushing these meds.

Exactly.

So to really understand this deep dive, let's not just like read through a textbook list.

Let's conceptualize this as a patient rolling through the hospital doors.

I like that approach.

Yeah.

So the first thing we almost always have to address is their brain and their pain.

Right.

We have to manage consciousness before we can do anything invasive.

Absolutely.

And we can actually start with something highly localized like intravenous regional anesthesia.

You'll often see this used for surgeries on extremities.

Okay.

Like an arm or a leg.

So the provider uses a tourniquet to essentially stop arterial blood flow into the limb and then injects a local anesthetic like lidocaine into a distal vein.

I've always thought of that like building a temporary chemical dam.

You're intentionally trapping the drug so it works exactly where you want it without affecting the rest of the body.

The mechanics of that dam are fascinating, honestly.

You remove the blood from the limb, often with an esmarch bandage, and then apply the tourniquet.

Usually a double tourniquet.

Yeah.

Usually a double tourniquet to ensure a complete lockade of arterial flow throughout the entire procedure.

So the lidocaine diffuses out of the vasculature and evenly distributes into the tissue.

Makes sense.

But here is the critical physiological catch that you have to monitor for.

When the surgery is over and you loosen that tourniquet, the dam breaks.

Oh, right.

And about 15 % to 30 % of that administered anesthetic is released directly into the systemic circulation all at once.

Wow.

That is a massive bolus hitting the central nervous system and the heart simultaneously.

It is.

So you have to be standing by for systemic toxicity.

But what if we need systemic control from the start?

Like we need to completely sedate the patient.

Well, then we've got opioids like remafentanil, which is unique because its effects terminate just like five to 10 minutes after the infusion stops.

Because it doesn't rely on the liver or kidneys, right?

Exactly.

It's metabolized by plasma and tissue esterases, so it clears incredibly fast.

Let's unpack this next one because I always struggled with this.

Dexmedetomidine.

Oh, Presodex.

Yeah.

Right.

Because you're trying to sedate initially intubated patients and you're terrified of depressing their respiratory drive to the point where they just can't be weaned off the vent.

And dexmedetomidine solves a lot of those exact problems.

It's a selective alpha -2 adrenergic agonist.

What makes it so valuable in an acute care setting is that it provides both sedation and analgesia, but it completely spares the respiratory drive.

So they're calm, pain -free, and their lungs are still working on their own.

Yes.

That sounds like the perfect drug.

It is highly effective, but because it activates alpha -2 receptors in the central nervous system and the periphery, it decreases the release of norepinephrine.

Ah.

Okay.

So you are essentially turning down the sympathetic nervous system.

Exactly.

So the primary adverse effects you must anticipate are hypotension and bradycardia.

Right.

Their heart rate could drop.

Yeah.

If the patient's heart rate drops too low, you might have to decrease the infusion rate, push IV fluids, elevate their lower extremities, or even administer a muscarinic antagonist like atropine to block the vagus nerve and bring the heart rate back up.

Got it.

We have to contrast that with some of the other heavy hitters, though, like Atomidate.

Yeah.

Atomidate puts someone under rapidly, but provides zero pain relief.

Which is wild.

Right.

And more importantly, doesn't it suppress plasma cortisol levels for like six to eight hours?

It does.

And if you have a septic patient whose body is already fighting for its life, blunting their natural stress response by dropping their cortisol can be incredibly dangerous.

Definitely.

Then there's ketamine, which puts the patient in a dissociative state and midazolam, you know, benzodiazepine that produces conscious sedation.

But midazolam brings up a vital safety alert from the chapter.

It carries a real risk of respiratory and cardiac arrest.

Okay.

If a patient experiences a dangerous midazolam overdose,

we do have a reversal agent called Flumazenil.

It's a competitive benzodiazepine receptor antagonist.

Wait, if we have a direct reversal agent, why wouldn't we just use it immediately any time a patient gets too sedated on a benzo?

You'd think so, but clinical judgment has to dictate that choice, because reversing the drug isn't without its own severe risks.

Really?

Like what?

Well, Flumazenil might reverse the sedative effects, but it doesn't reliably reverse the respiratory depression.

Oh, wow.

I didn't realize that.

Yeah.

Furthermore, its principal adverse effect is the precipitation of life -threatening seizures.

Oh, jeez.

If you administer this to a patient who is physically dependent on benzodiazepines or someone who takes them to manage epilepsy,

the sudden withdrawal at the receptor level can trigger intractable seizures.

So the risks frequently outweigh the benefits.

Exactly.

Consulting a toxicologist is highly recommended before pushing it.

Triggering a seizure while trying to fix over -sedation is like a terrifying cascade to manage.

Definitely.

Let's look at another major warning in the text, this time for spinal and epidural anesthesia.

The guidelines are explicitly clear regarding bupivacaine.

You must never use the highly concentrated 0 .75 % solution in obstetric patients.

And the physiology supports that absolute contraindication, right?

It does.

In pregnant patients, that high concentration carries an unacceptable risk of refractory, fatal cardiac arrest if it inadvertently enters the systemic circulation.

That's terrifying.

Let's shift from sedation to strict pain control.

5e acetaminophen is common, but it has strict weight -based dosing limits.

Right, a daily max of 4 ,000 mg for a standard adult.

And if there is an overdose, the liver is at risk.

The antidote is acetylcysteine.

But the text details a very specific three -bag sequential infusion method, doesn't it?

Yeah, you don't just hang a bag and walk away.

You give the first bag over 15 to 60 minutes, the second over 4 hours, and the third over 16 hours.

Okay, good to know.

But opioids are obviously the primary tools for acute pain.

If a patient is overly depressed from an opioid, how do we reverse it without completely unmasking their surgical pain?

That requires meticulous titration of meloxone.

The clinical objective isn't to remove all the opioid from the receptors.

Right, you don't want them screaming in pain.

Exactly.

It's to achieve adequate ventilation and alertness without slamming the patient into excruciating pain.

So you administer it in very small doses every two to three minutes until you get a satisfactory respiratory response.

Okay, but opioids don't just affect the brain, right?

They severely affect the gut.

Yeah, they cause an opioid -induced ileus.

They essentially paralyze the bowel.

This is where a highly targeted drug like alveopan comes into play.

Right.

It is a selective, peripherally acting mu -opioid antagonist.

It blocks the opioid receptors in the gastrointestinal tract to speed up bowel recovery after surgery.

Okay.

But because of its chemical structure, it has a very limited ability to cross the blood -brain barrier.

Wait, so it blocks the opioids in the gut, waking the bowel up, but leaves the opioids in the brain alone so the patient keeps their pain relief?

That's the core of it, yeah.

That's amazing.

It is, however, long -term use has been associated with an increased incidence of myocardial infarction.

Oh, of course.

There's always a catch.

Always.

Because of that cardiac risk, it is strictly limited to short -term, seven -day use only in hospitalized patients.

Hospitals actually have to enroll in a specific FDA program just to dispense it.

Wow.

Rounding out analgesia, we have 5e NSAIDs like Ketrolac.

The golden rule there is that treatment must not exceed five days total.

Right.

Whether it's IV, IM, or oral.

Because of the profound risk of GI bleeding and renal impairment.

All right.

So our patient's pain and consciousness are managed.

But what if they are fighting the ventilator?

We need to secure the airway and take over their breathing entirely.

This brings us to neuromuscular blockers, completely paralyzing the muscles.

Let's decode table 94 .1 from the text, which compares competitive and depolarizing neuromuscular blockers.

Sure.

So all of these drugs share one main indication,

muscle relaxation.

And because they paralyze the diaphragm, they all share the severe risk of respiratory depression.

When I look at the competitive blockers like atracurium, pancoronium, and racharonium, I visualize them like changing the locks on a door.

That's a great analogy.

The body's natural key is acetylcholine.

These drugs sit in the lock, the nicotinic receptor, so acetylcholine can't get in to activate the muscle.

Exactly.

They cause a competitive blockade, preventing the normal physiological trigger for muscle contraction.

Clinically, you differentiate them based on their side effect profiles.

For instance, some competitive agents like atracurium and myvicurium promote the release of histamine from mast cells, which can cause sudden hypotension.

Others, like racharonium and vecuronium, do not trigger that histamine release, making them cleaner options for patients with cardiovascular instability.

Good distinction.

Then we get to the depolarizing agents.

In the U .S., secnocolene is the only one in clinical use.

Right.

But wait, I'm confused about the clinical presentation of this one.

If our goal is to completely paralyze the patient, why does secnocolene cause them to twitch and contract first?

That seems completely counterintuitive.

It does seem paradoxical until you look at the motor end plate.

Secnocolene structurally resembles acetylcholine.

When you push the drug, it binds to those nicotinic receptors and actually triggers them, causing a brief period of depolarization, which you see clinically as those transient muscle fasciculations or twitches.

But unlike normal acetylcholine, which detaches rapidly, secnocolene binds and it stays bound.

So it essentially short -circuits the muscle by turning it on and refusing to let it reset.

Exactly.

It creates a constant state of depolarization.

Because the muscle can't repolarize, it becomes unresponsive to further stimulation, resulting in complete flaccid paralysis.

And the most critical takeaway for a clinician is its time course.

Secnocolene is ultra -short -acting.

Paralysis peaks in just one minute.

One minute.

That is fast.

Because of this violently rapid onset, you must have all airway management equipment ready, checked, and at the bedside before the drug enters the vein.

You do not have time to go looking for a laryngoscope once the patient starts twitching.

Absolutely not.

Once that airway is locked down, you've bought time.

But what if the monitor starts alarming, the blood pressure is crashing, or the heart rhythm is completely erratic?

We have to address the cardiovascular crisis – balancing, bleeding, clotting, and the pump itself.

Let's start with the plumbing and anticoagulation.

We have continuous, unfractionated heparin infusions, which require constant monitoring of APTT or anti -ZC levels to ensure the blood isn't too thin.

Right.

Versus low -dose subcutaneous prophylaxis, which is safe enough not to require monitoring.

And if a patient on a heparin infusion starts bleeding out, you have to reverse it quickly.

The antidote is protamine sulfate.

And the math is straightforward there.

One milligram of protamine inactivates 100 units of heparin.

But some patients develop a severe immune reaction called heparin -induced thrombocytopenia, or HIT.

Yeah, for them we use direct thrombin inhibitors like argotrobin.

There is also bivaliridin, which has a very short 25 -minute half -life and is used primarily during percutaneous coronary interventions.

Okay, I have to mention this because I found a detail in this section absolutely fascinating.

There is a drug called antithrombin, specifically the recombinant version called atrin, used to inhibit coagulation in patients with an inherited antithrombin deficiency.

Yes, the goat one.

It is produced by goats that have been given human DNA, and they express this human antithrombin right into their milk.

I mean, what?

It is wild, right?

It's a brilliant application of recombinant DNA technology.

Patients with this deficiency are typically on lifelong warfarin to prevent clots.

But if they face surgery or childbirth, you have to stop the warfarin to prevent them from pleading to death, which instantly spikes their thrombosis risk.

Preachin bridges that gap safely using a protein harvested from goat milk.

Incredible.

We also have the glycoprotein Ibea antagonists.

The text refers to drugs like epsiximab, eptofibatide, and terafibon as super aspirins.

Why did they get that title?

Because they cause a reversible blockade of the GP Iberia receptors on the surface of platelets.

This is the absolute final step in platelet aggregation.

So no matter what starts the process, they stop it.

Exactly.

It doesn't matter what stimulated the platelet in the first place, whether it was collagen from a torn vessel, thromboxane A2, or thrombin, these drugs block the final pathway that allows platelets to link together.

Got it.

They are incredibly potent and essential for preventing ischemic events in acute coronary syndrome.

But what if the clot has already formed, like in a massive stroke or an MI?

We look at the clinical guidelines in tables 94 .2 and 94 .3 for thrombolytics, the clot busters.

Right.

Alteplase, or TPA, has been the standard.

But the text positions tenecteplase as a major game changer.

Why is it superior?

It comes down to pharmacokinetics and the logistics of emergency care.

Tenecteplase is a variant of TPA, but it's been engineered to be 80 times more resistant to circulating inhibitors in the blood.

Oh, wow.

This gives it a much longer half -life, like 20 to 24 minutes compared to TPA's five minutes.

So instead of needing a complex 90 -minute infusion on an IV pump like TPA requires, you can give Tenecteplase much faster.

Yes, you can give it as a single five -second intravenous bolus.

Five seconds.

A paramedic can administer it in the back of an ambulance before the patient even reaches the hospital doors.

That's huge.

The ASCENT2 trial actually demonstrated it was just as safe and effective as TPA, but with a lower incidence of non -intracranial major hemorrhage.

But with any clot buster, you must rigorously screen the patient against the absolute contradictions listed in Table 94 .3.

Absolutely.

If they have any prior intracranial hemorrhage, known structural cerebral vascular lesions, a suspected aortic dissection, or active internal bleeding, you cannot push the drug.

The risk of a fatal bleed is simply too high.

Exactly.

Let's move from the plumbing to the electrical system.

Anadysrhythmics.

We use lidocaine intravenously, strictly, for ventricular dysrhythmias.

But you have to watch closely for central nervous system toxicity, like confusion or seizures.

Then there's amyoteroin, which targets the AV node.

The text specifically notes that high concentrations of amyoteroin cause severe phlebitis.

Yeah, it literally inflames the veins, so it really should be given through a central line and you have to monitor for profound hypotension.

And then we have adenosine, the drug of choice for paroxysmal supraventricular tachycardia, or SVT, where the heart is beating dangerously fast due to a loop in the electrical pathway.

I remember seeing this push for the first time.

The patient is awake, their heart is racing at 180 beats a minute, and you push adenosine.

We are literally stopping their heart to reset it, aren't we?

In a physiological sense, yes.

Adenosine greatly slows conduction through the AV node.

When you look at the ECG monitor, the most prominent change is a prolonged PR interval.

But it is entirely expected to see a brief period of total assistal, a literal flat line lasting several seconds immediately after the injection.

Watching that monitor go flat feels like an eternity in the room.

It is so stressful.

But its half -life is incredibly short, estimated at just 1 .5 to 10 seconds in the blood.

Okay, so it clears super fast.

Because it clears so rapidly, you must administer it as a rapid IV push as close to the heart as physically possible, usually followed immediately by a rapid saline flush to force it into the central circulation before it metabolizes.

They also have to assess their current medications, right?

Yes.

Methylxanthines, like caffeine or the asthma drug theophiline, competitively block adenosine receptors.

So a patient who takes theophiline daily will require a significantly larger dose of adenosine to achieve that electrical reset.

Exactly.

Let's look at the pump itself now.

Heart failure and hypertensive emergencies.

For acute decompensated heart failure, we reach for IFA inotropes to help the heart squeeze harder.

Dopamine is a fascinating choice because its mechanism changes depending on the dose.

At low doses, it primarily hits dopamine receptors in the kidneys to dilate blood vessels and increase urine output.

At moderate doses, it hits beta -1 receptors in the heart to increase contractility.

But if you push to very high doses, it hits alpha -1 receptors, causing massive vasoconstriction.

Which is dangerous because that increases vascular resistance, making it harder for the heart to pump, which can actually reduce cardiac output.

Because of that alpha -1 vasoconstriction risk at high doses, dobutamine is often preferred for short -term heart failure treatment.

How is it different?

Dobutamine is a selective beta -1 agonist.

It directly increases myocardial contractility without activating those alpha -1 receptors, so it doesn't increase the afterload the heart has to pump against.

Oh nice.

You might also see melronone used, right?

Yeah, it's a phosphodiesterase inhibitor, often called an inodilator, because it simultaneously increases contractility and promotes vasodilation.

However, it's reserved for severe heart failure because it carries a significant risk of inducing fatal dysrhystmias.

What about pure vasodilators?

The tech spends a lot of time on deseratide, which is a synthetic brain natriuretic peptide, or BNP.

In theory, this sounds like a miracle drug for heart failure.

The underlying theory made perfect sense.

BNP naturally dilates arterioles in veins, which should reduce both preload and afterload, taking the strain off a failing heart.

But the text outlines a massive cautionary tale regarding the ASCEND -HF trial.

When they studied over 7 ,000 patients, this massive trial found deseratide offered no clinical benefit.

No benefit at all.

None.

It didn't reduce rehospitalization rates or 30 -day mortality compared to a placebo.

Worse, it nearly doubled the incidence of severe hypotension.

The primary takeaway for clinicians is that evidence trumps theory.

Deseratide cannot be recommended for routine use.

For true hypertensive emergencies, where a skyrocketing blood pressure is actively destroying end organs like the brain or kidneys, we use IV nitroproside.

The speed of this drug is astounding.

It drops blood pressure in seconds.

But its metabolism hides a very dark secret.

It really does.

The chemical structure of nitroproside contains five cyanide groups.

Cyanide.

Yeah, cyanide.

When the drug enters the smooth muscle and metabolizes to release nitric oxide, which causes the vasodilation, it splits those cyanide groups free into the bloodstream.

Yikes.

The liver then has to convert that cyanide into a less toxic substance called thiocyanate, a process that requires thiosulfate as a co -enactor.

Wait, so by treating their blood pressure, you are actively infusing them with cyanide?

Essentially, yes.

If you infuse nitroproside too rapidly, or if the patient has underlying liver disease or depleted thiosulfate stores,

lethal amounts of cyanide can accumulate.

How do you prevent that?

You minimize this risk by avoiding rapid infusion rates and occasionally co -administering thiosulfate.

You also have to monitor their mental status closely.

Why mental status?

Because if they are on the infusion for several days, the thiocyanate itself can accumulate and cause severe central nervous system toxicity, presenting as delirium or psychosis.

That is wild.

We have a few safer targeted options for blood pressure too.

Phenol -Dipam drops blood pressure but activates dopamine 1 receptors to maintain or even improve renal blood flow, protecting the kidneys.

Right.

Lobetolol blocks both alpha and beta receptors, so you drop the pressure without the heart rate shooting up in a reflex tachycardia.

And clavitapine is a calcium channel blocker with an ultra -short half -life of just 1 minute, allowing you to titrate the blood pressure minute by minute with incredible precision.

Protecting renal perfusion with drugs like phenol -Dipam highlights our next priority.

We've supported the brain, the lungs, the heart, and the vessels.

Now we need to support the downstream organs that took a hit during the crisis, specifically the blood and the kidneys.

Right.

Looking at hematology, if our patient has severe anemia and requires parenteral iron, the text highlights a massive black box warning for iron dextrin.

It's vital to understand the mechanism behind that warning.

Yeah.

The most serious adverse effect is potentially fatal anaphylaxis.

Yes.

But the anaphylactic reactions aren't triggered by the iron itself, they are an immune response to the dextrin molecule in the formulation.

Exactly.

So you can't just hang the bag, set the pump, and walk out of the room.

Absolutely not.

The guidelines mandate administering a small test dose first.

And even then, the text warns that a fatal anaphylactic reaction can still occur with the full therapeutic dose, even if the patient tolerated the test dose perfectly.

Wow.

You must have injectable epinephrine and full resuscitation facilities immediately at hand whenever this drug is infusing.

I noticed the guidelines point out much safer alternatives, specifically for patients with chronic kidney disease.

Drugs like sodium ferric gluconate complex, iron sucrose, and ferrimoxytol.

Right.

They pose very little risk of anaphylaxis, which means there is no need for a test dose.

They are just restricted by FDA approval, mostly to the CKD population.

And speaking of the kidneys, we have to talk about acute diuresis.

If the patient develops acute pulmonary edema fluid backing up into their lungs, we push a loop diuretic like IV furosemide.

But the text also details a highly specialized osmotic diuretic, mannitol.

This mechanism blew my mind, honestly.

How does a simple six -carbon sugar act as a powerful diuretic?

It's just a sugar molecule.

It acts purely on the principles of physics and osmotic pressure within the nephron.

Mannitol is freely filtered at the glomerulus, meaning it easily passes from the blood into the renal tubules.

But unlike sodium or water, which the kidney constantly tries to reabsorb, mannitol undergoes minimal tubular reabsorption.

It just sits there inside the tubule.

Because it's a large concentrated molecule, it creates a powerful osmotic force that physically holds onto water, preventing the kidney from reabsorbing it back into the blood.

So wherever mannitol goes, water is trapped and dragged along with it straight to the bladder.

Precisely.

This makes it an incredible tool for preventing irreversible renal failure during hypervolemic shock.

Because it forcefully draws water into the tubule, it maintains urine flow even when the kidneys are trying to shut down from a lack of blood pressure.

Yes.

It's also used to draw edematous fluid out of the brain to lower dangerously high intracranial pressure or out of the eye to lower intraocular pressure.

But there is a huge safety alert tied to that exact same mechanism.

If mannitol leaks out of the capillary beds anywhere else in the body before it reaches the kidneys, it takes that water with it and causes massive tissue edema.

That's the danger.

If a patient already has heart failure or pulmonary edema, dragging more fluid into their tissues could be lethal.

So if signs of pulmonary congestion develop during a mannitol infusion, the clinical directive is to stop the infusion immediately.

Exactly.

Finally, we manage the electrolytes.

The Vaptin, Skonovaptin, and Tolvaptin are vasopressin receptor antagonists.

They block the V2 receptors in the collecting ducts of the kidneys, right?

Vasopressin normally tells the kidneys to hold on to water.

By blocking it, you force the kidneys to excrete large volumes of free, unconcentrated water.

Which means the sodium left behind in the blood becomes more concentrated, indirectly raising serum sodium levels for patients suffering from severe hyponatremia.

But there is a severe neurological risk here.

Because these drugs are so effective at clearing water, they can cause a rapid overcorrection of sodium levels.

What happens if it corrects too fast?

If the serum sodium rises too fast, the sudden osmotic shift in the brain can strip the myelin sheath off nerve cells, causing osmotic demyelination syndrome, or ODS.

Oh, that's terrible.

It is a devastating permanent neurological injury.

Frequent monitoring of serum sodium levels during therapy is an absolute requirement to ensure you aren't correcting it too quickly.

That is an immense amount of pharmacology and physiology to synthesize.

It really is.

As we wrap up this deep dive into chapter 94,

it brings us to a final, provocative thought about the nature of our work.

Yeah, I really want you to mull over the incredible paradox of acute care pharmacology.

We use highly targeted, sometimes highly toxic molecules to essentially hijack the body's native systems in order to save it.

It's so true.

We literally stop the heart's electrical system with adenosine to save its rhythm.

We chemically paralyze the diaphragm with secondylcholine to save the lungs.

We infuse cyanide -laced molecules like nitroproside to save the vasculature from tearing apart.

Exactly.

Having this kind of power at your fingertips demands absolute unwavering respect for the compensatory mechanisms we are overriding.

It really is a high -speed car chase.

And as a clinician, you have to know exactly when to hit the brakes and when to hit the Don't listen to better.

We encourage you to take these pathophysiological frameworks and apply them directly to your clinical practice in your upcoming exams.

On behalf of the Last Minute Lecture team, thank you for joining us.

Keep studying and keep diving deep.